Related Experiment Video
Updated: Sep 14, 2025

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
Published on: July 31, 2019
Gut microbiota-modulating potential of sweet potato-derived dietary fiber for type 2 diabetes management
Lanlan Hu1, Zhen Wang1, Longfei Feng1
1School of Food Science, Henan Institute of Science and Technology, Xinxiang, China.
Background:
Diabetes mellitus presents a significant global health burden, highlighting the need for safe and cost-effective dietary interventions. Soluble dietary fiber (SDF) derived from sweet potato, rich in bioactive compounds, holds promise for improving glucose metabolism and gut microbiota, yet its effects on type 2 diabetes (T2D) remain underexplored.
Results:
The present study investigated the impact of different doses of sweet potato-derived SDF-high (SDF-H, 1000 mg kg-1 body weight), SDF-medium (SDF-M, 600 mg kg-1 body weight) and SDF-low (SDF-L, 200 mg kg-1 body weight) on T2D mice over 10 weeks. The results demonstrated that SDF supplementation significantly improved body weight, reduced excessive water intake and lowered postprandial blood glucose. Notably, high- and medium-dose SDF improved glucose tolerance, reducing postprandial blood glucose by 23.76% and 17.10%, respectively, and mitigated diabetes-induced damage to the liver, kidneys and pancreas. SDF also modulated lipid metabolism, decreasing serum total cholesterol and triglycerides at the same time as increasing high-density lipoprotein cholesterol. Importantly, SDF, particularly at high doses, enhanced gut microbiota diversity and abundance, suppressing harmful bacteria and promoting beneficial genera such as Alloprevotella and Lactobacillus, at the same time as decreasing the abundance of Helicobacter. These findings suggest that sweet potato-derived SDF exerts multi-targeted benefits in T2D through metabolic regulation and gut microbiota modulation.
Conclusion:
Sweet potato-derived SDF is a promising natural agent for improving glycemic control, lipid profiles, and gut microbial balance in T2D, suggesting its potential as a dietary intervention for diabetes management, pending further validation in human studies. © 2025 Society of Chemical Industry.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Diabetes Mellitus: Type 2 and Gestational
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Glucose Absorption Into the Small Intestine
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Biguanides and Glitazones

